Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06600815

Analgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After TKA

This is a single-center prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before total knee arthroplasty (TKA). Eligible patients will be included in this study after signing the informed consent form. Before TKA, the patients will be randomly assigned to either a preemptive stepwise infiltration anaesthesia (PSIA) group or a postoperative local infiltration analgesia (PLIA) group and administered different pain management protocols during surgery. Clinical evaluation will be conducted at baseline, before surgery, and at 6, 12, 24, 48, and 72 hours postoperatively, as well as during follow-up visits at 3 weeks, 6 weeks and 6 months postoperatively. All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the end of total knee arthroplasty and 6, 12, 24, 48, 72, and 96 weeks later, aimed at comparing the postoperative pain and inflammatory response between PSIA and PLIA, to explore the optimal perioperative analgesic modality for TKA.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Location status: Recruiting

Location contact

Fang, Vice directors

CONTACT

[email protected]

About this study

This is a single-center prospective cohort study in which patients were evaluated by inclusion and exclusion criteria before total knee arthroplasty (TKA). This study aims to recruit 110 patients across a single centre over 1 year. Eligible patients will be included in this study after signing the informed consent form. Before TKA, the patients will be randomly assigned to either a preemptive stepwise infiltration anaesthesia (PSIA) group or a postoperative local infiltration analgesia (PLIA) group and administered different pain management protocols during surgery. Clinical evaluation will be conducted at baseline, before surgery, and at 6, 12, 24, 48, and 72 hours postoperatively, as well as during follow-up visits at 3 weeks, 6 weeks and 6 months postoperatively. The primary outcomes are the amount of morphine consumed within 0-24 hours postsurgery and the visual analogue scale (VAS) score postsurgery. Secondary outcomes include the time to first rescue analgesia, total morphine consumption during hospitalization, postoperative joint function (measured by the Hospital for Special Surgery [HSS] score and knee joint range of motion [ROM]), intraoperative bleeding and serological indicators. All patients voluntarily participated in the study and signed informed consent. During the treatment period, all prospective patients underwent clinical evaluation at the end of total knee arthroplasty and 6h, 12h, 24h, 48h, 72h, 3 weeks, 6 weeks and 6 months later, aimed at comparing the postoperative pain and inflammatory response between PSIA and PLIA, to explore the optimal perioperative analgesic modality for TKA. Statistical analyses utilizing regression models and survival analysis will be conducted to assess the relationships between the pain management method and postoperative pain and efficacy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must meet all of the following criteria to be eligible for inclusion:

  • Clinical diagnosis of primary unilateral knee osteoarthritis (KOA), confirmed by imaging as KOA (Kellgren-Lawrence score ≥2). The patient was scheduled for initial unilateral total knee arthroplasty (TKA) at our hospital.
  • Preoperative American Society of Anaesthesiologists (ASA) score ranging from 1 to 3. Surgeons deemed the patient eligible for TKA based on the evaluation criteria.
  • Participants aged 18 years or older, both male and female.
  • Ability to provide informed consent and sign a written informed consent form.
  • The ability to comprehend the research requirements and willingness to cooperate with the study instructions.

Exclusion criteria

Patients will be excluded if they meet any of the following criteria:

  • Previous knee surgery on the operative knee or a history of infection in the operative knee.
  • Patients diagnosed with conditions other than osteoarthritis (including rheumatoid arthritis, traumatic arthritis, septic arthritis and haemophilic arthritis).
  • Severe osteoarthritis (including flexion contracture >30° or varus/valgus deformity >30° and the use of unconventional arthroplasty components due to complex joint pathology [e.g., restrictive prostheses]).
  • Allergy to the investigational drug.
  • The presence of neuromuscular dysfunction on the operative side.
  • Dependence on anaesthesia drugs (defined as the use of opioid or local anaesthetic drugs exceeding 100 mg of morphine equivalents per week to control preoperative pain for more than 3 months).
  • Poor overall health conditions, including but not limited to a glycated haemoglobin level exceeding 12%; blood pressure exceeding 170/110 mmHg; myocardial infarction, stroke, transient ischaemic attack, acute congestive heart failure, or any acute coronary events within the past 6 months; severe hepatic or renal dysfunction; and pregnancy or lactation.
  • Concurrent participation in clinical trials other than this trial.

Treatment and study plan

preemptive stepwise infiltration anaesthesia(PSIA)

Procedure

For PSIA patients, the anaesthetic is administered in stages. Initially, CA is injected at the incision site before the medial parapatellar incision. Following skin incision, more CA is injected into the subcutaneous tissue. After exposing the fascial layer and joint capsule, CA is used around the patellar tendon, and then CB is injected into the joint capsule and surrounding muscles. Additional CB is applied to the synovium and soft tissues after the joint cavity is opened, and more is used in the posterior joint capsule after bone resection.

postoperative local infiltration analgesia(PLIA)

Procedure

Before standardized TKA and implantation of the prosthesis, 30-40 mL of CB will be used to infiltrate the synovium and whole joint capsule. Subsequently, the joint cavity, subcutaneous tissue, and skin will be closed layer by layer using routine procedures. After the skin is closed, 30-40 mL of CA will be injected into the skin and subcutaneous tissue.

Primary outcomes

  1. Postoperative morphine consumption within the first 24 hours

    Time frame: the first 24 hours after TKA

    Postoperative morphine consumption within the first 24 hours includes both routine analgesia and rescue analgesia, which will be converted to oral morphine equivalents (OMEs)

  2. . Postoperative visual analogue scale (VAS) scores at 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 3 weeks, 6 weeks and 6 months

    Time frame: 6 hours, 12 hours, 24 hours, 48 hours, 72 hours, 3 weeks, 6 weeks and 6 months after TKA

    VAS scores are the most commonly used indicator for assessing the intensity of patient pain (15). The scale ranges from "0" to "10", where "0" indicates no pain and "10" represents the most severe pain that is unbearable. Patients will rate their pain based on subjective perceptions. In this trial, VAS scores will be recorded once before TKA. The VAS scores will be assessed separately for the resting and flexion states. If the patient's hospitalization period is shorter than 72 hours, the VAS score at discharge will be recorded instead of that at 72 hours. Studies have shown that some patients still experience joint pain six months after TKA. The VAS scores of patients at 6 months after TKA will be evaluated. A VAS score of 4 or above is defined as "chronic persistent pain after TKA." The results will be used to evaluate whether PSIA can reduce pain after TKA.

Secondary outcomes

  1. Postoperative time to first rescue analgesia

    Time frame: up to 3 days

    Rescue analgesia will be initiated when the patient reports local knee joint pain on the operative side with a VAS score > 4. The specific steps will be implemented as described previously. The time to rescue analgesia will be recorded.

  2. Total morphine consumption during hospitalization

    Time frame: through study completion, an average of 6 months

    It will be converted to total morphine equivalents and will include both the postoperative routine pain management regimen and rescue analgesia.

  3. The Hospital for Special Surgery Knee Score (HSS)

    Time frame: 3 weeks, 6 weeks and 6 months postoperatively

    The Hospital for Special Surgery Knee Score (HSS) is a patient-reported questionnaire specific to the knee joint, with a total score of 100 points. It comprises six scoring components: pain (30 points), function (22 points), range of motion (18 points), muscle strength (10 points), knee deformity (10 points) and stability (10 points). Additional points are deducted for the use of assistive devices, extension lag and varus deformity: up to 3 points for assistive device use, up to 5 points for extension lag and 1 point deducted for every 5 degrees of varus deformity. The scores are classified as follows: ≥ 85 as "Excellent", 70-84 as "Good", 60-69 as "Fair", and < 60 as "Poor". The HSS score is widely praised for its perceived ease of use and quick recording and has been shown to be an effective and reliable measure for assessing the efficacy of TKA.

  4. Range of motion (ROM)

    Time frame: 3 weeks, 6 weeks and 6 months postoperatively

    The range of motion (ROM) will be measured with a protractor thrice daily at 6-hour intervals, and the best value on each day will be used in the analysis. The range of motion (ROM) is from 0 to 180 degrees. The larger the angle, the more satisfactory the recovery of joint function.

  5. Direct intraoperative bleeding

    Time frame: 24 hours postoperatively

    Intraoperative bleeding will be recorded directly by anesthesiologists (mL).

  6. Indirect intraoperative bleeding

    Time frame: 24 hours postoperatively

    Intraoperative bleeding will be estimated by subtracting the preoperative hemoglobin level from the hemoglobin level measured 24 hours postoperatively.

  7. Complete blood count

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    A complete blood count (CBC) can reflect the patient's postoperative inflammatory status. It measures various components of the blood, including white blood cells, red blood cells, and platelets, which can indicate the presence of inflammation or infection. An elevated white blood cell count, for example, is often associated with an inflammatory response.

  8. C-reactive protein (CRP)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    C-reactive protein (CRP) can reflect the patient's postoperative inflammatory status.

  9. Erythrocyte sedimentation rate (ESR)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Erythrocyte sedimentation rate (ESR) can reflect the patient's postoperative inflammatory status.

  10. Interleukin-6 (IL-6)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Interleukin-6 (IL-6) can reflect the patient's postoperative inflammatory status.

  11. Total bilirubin (TB)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Total bilirubin will be used to evaluate the impacts of surgical trauma and medications on patients.

  12. Derect bilirubin (DB)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Derect bilirubin will be used to evaluate the impacts of surgical trauma and medications on patients.

  13. Aspartate aminotransferase (AST)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Aspartate aminotransferase will be used to evaluate the impacts of surgical trauma and medications on patients.

  14. Alanine aminotransferase (ALT)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Alanine aminotransferase will be used to evaluate the impacts of surgical trauma and medications on patients.

  15. Creatinine (Cr)

    Time frame: 72 hours, 3 weeks, 6 weeks and 6 months postoperatively

    Creatinine will be used to evaluate the impacts of surgical trauma and medications on patients.

Other outcomes

  1. Age

    Time frame: through study completion, an average of 6 months

    Age in years will be obtained from the electronic medical records system.

  2. Sex

    Time frame: through study completion, an average of 6 months

    Sex (male or female) will be obtained from the electronic medical records system.

  3. Operative site

    Time frame: through study completion, an average of 6 months

    Operative site (left or right) will be obtained from the electronic medical records system.

  4. BMI

    Time frame: through study completion, an average of 6 months

    Weight (kg) and height (m) will be combined to report BMI in kg/m^2, which will be obtained from the electronic medical records system. This information will be collected by the same evaluator and used to calculate the age-corrected Charlson Comorbidity Index (aCCI), baseline ROM, HSS score and VAS score for these patients.

  5. Time of operation

    Time frame: through study completion, an average of 6 months

    Inpatient data will include the operative time and time to discharge. These inpatient data will be sourced from the electronic medical records system and used to evaluate the impacts of PSIA and PLIA on the surgical process and postoperative recovery.

  6. Operative time

    Time frame: through study completion, an average of 6 months

    Operative time will be sourced from the electronic medical records system and used to evaluate the impacts of PSIA and PLIA on the surgical process and postoperative recovery.

  7. Time to discharge

    Time frame: through study completion, an average of 6 months

    Time to discharge will be sourced from the electronic medical records system and used to evaluate the impacts of PSIA and PLIA on the surgical process and postoperative recovery.

  8. Incidence of Adverse events (AEs)

    Time frame: through study completion, an average of 6 months

    Adverse events (AEs) are adverse medical events that occur in clinical trial subjects after receiving treatment. In this study, total AEs will be mainly categorized into local AEs and systemic AEs. Local AEs include but are not limited to prolonged wound drainage (wound drainage persists on postoperative day 3, and the drainage area of the wound dressing is greater than 2×2 cm , poor wound healing and prosthetic joint infection. Systemic AEs include but are not limited to deep vein thrombosis events, systemic infection and serious adverse events such as pulmonary embolism and death.

  9. Likert score

    Time frame: through study completion, an average of 6 months

    We will use a Likert scale to evaluate participants satisfaction with each treatment phase at each assessment. This scale consists of 5 levels (very dissatisfied, dissatisfied, neutral, satisfied and very satisfied) from 1 to 5. After the final follow-up, the total score on the Likert scale for each participant will represent their overall satisfaction to date. The larger the score, the more satisfactory with the participants.

Study contacts

Contact information is provided by the study sponsor or research team.

Xinyu Fang, MD

CONTACT

[email protected]

18084768503 Ext. 86

Sponsors and collaborators

Lead sponsor

First Affiliated Hospital of Fujian Medical University

Other

Registry information

Official study title

Analgesic Efficacy of Preemptive Stepwise Infiltration Anesthesia for Perioperative Analgesia After Total Knee Arthroplasty: a Prospective Double-blind Randomized Controlled Clinical Trial

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 19, 2024
Registry last updated
Oct 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.